World Asset Management Inc Lowers Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

World Asset Management Inc lowered its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 10.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,726 shares of the biopharmaceutical company’s stock after selling 558 shares during the period. World Asset Management Inc’s holdings in Regeneron Pharmaceuticals were worth $1,479,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Joel Isaacson & Co. LLC raised its holdings in shares of Regeneron Pharmaceuticals by 0.8% in the 1st quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $1,249,000 after acquiring an additional 25 shares in the last quarter. Cornerstone Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 3.7% during the 1st quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 30 shares in the last quarter. Comprehensive Portfolio Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 4.1% during the 1st quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 33 shares in the last quarter. Rehmann Capital Advisory Group raised its holdings in shares of Regeneron Pharmaceuticals by 31.3% during the 1st quarter. Rehmann Capital Advisory Group now owns 210 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 50 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. raised its holdings in shares of Regeneron Pharmaceuticals by 10.6% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 606 shares of the biopharmaceutical company’s stock valued at $249,000 after buying an additional 58 shares in the last quarter. 66.74% of the stock is currently owned by hedge funds and other institutional investors.

REGN has been the topic of a number of research reports. TheStreet cut Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Wednesday, June 5th. BidaskClub upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, July 19th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 18th. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating on the stock in a research report on Wednesday, May 8th. Finally, Cantor Fitzgerald reduced their price target on Regeneron Pharmaceuticals from $441.00 to $405.00 and set a “neutral” rating on the stock in a research report on Monday, May 13th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $394.65.

Shares of REGN stock traded up $2.89 during trading hours on Thursday, reaching $307.65. The company’s stock had a trading volume of 477,962 shares, compared to its average volume of 787,381. The company has a market capitalization of $33.47 billion, a PE ratio of 15.54, a P/E/G ratio of 1.44 and a beta of 1.11. Regeneron Pharmaceuticals Inc has a one year low of $287.66 and a one year high of $442.00. The business’s fifty day moving average is $306.80. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. Regeneron Pharmaceuticals’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.67 earnings per share. Analysts expect that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current year.

In other news, EVP Neil Stahl sold 9,853 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total value of $3,012,456.22. Following the completion of the transaction, the executive vice president now owns 47,450 shares in the company, valued at approximately $14,507,363. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The disclosure for this sale can be found here. 11.84% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.